Kathmere Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Kathmere Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.41M	Buy	23,174 +12,880	+125%	+$751K	0.09%	159
2025 Q4	$555K	Buy	10,294 +4,897	+91%	+$236K	0.04%	298
2025 Q3	$243K	Sell	5,397 -3,851	-42%	-$180K	0.02%	441
2025 Q2	$428K	Sell	9,248 -326	-3%	-$16K	0.03%	309
2025 Q1	$584K	Sell	9,574 -1,064	-10%	-$62K	0.05%	219
2024 Q4	$602K	Buy	10,638 +2,656	+33%	+$148K	0.05%	197
2024 Q3	$413K	Buy	+7,982	New	+$374K	0.04%	234
2024 Q2	–	Sell	-4,096	Closed	-$222K	–	342
2024 Q1	$222K	Buy	+4,096	New	+$209K	0.03%	294
2023 Q3	–	Sell	-3,582	Closed	-$229K	–	268
2023 Q2	$229K	Buy	3,582 +70	+2%	+$4.69K	0.04%	208
2023 Q1	$243K	Sell	3,512 -969	-22%	-$68.3K	0.04%	175
2022 Q4	$322K	Buy	+4,481	New	+$338K	0.06%	136
2021 Q1	–	Sell	-2,531	Closed	-$157K	–	160
2020 Q4	$157K	Hold	2,531	–	–	0.03%	141
2020 Q3	$153K	Buy	+2,531	New	+$152K	0.04%	129
2020 Q1	–	Sell	-5,902	Closed	-$379K	–	87
2019 Q4	$379K	Buy	+5,902	New	+$338K	0.14%	68

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kathmere Capital Management's BMY Position: Q1 2026 in Review

Kathmere Capital Management increased its Bristol-Myers Squibb (BMY) stake by 125% in Q1 2026, buying an estimated $751K and bringing the position to 23,174 shares worth $1.41M. The position accounts for 0.09% of the portfolio, ranked #159.

Kathmere Capital Management first reported a position in BMY in Q4 2019 and has held it in 14 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Kathmere Capital Management held 23,174 shares of Bristol-Myers Squibb worth $1.41M as of Q1 2026.
Kathmere Capital Management bought 12,880 Bristol-Myers Squibb shares in Q1 2026, an estimated $751K.
Bristol-Myers Squibb made up 0.09% of Kathmere Capital Management's portfolio in Q1 2026, its #159 holding.
Kathmere Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 14 quarters since.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Kathmere Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.